Pfizer (PFE)

Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) announced better-than-expected revenue in Q3 2026, with revenue up 39.2% year on ...

Amgen's growth engine and Pfizer's value appeal pull in opposite directions, and the valuation gap between them is wider than many expect.

The patent-expiry question is still open: whether cutting costs now buys enough time for late-stage trials to replace fading blockbuster revenue.

Pfizer (NYSE:PFE) reported third-quarter 2026 revenue of $16.6 billion and raised its full-year outlook, citing growth in non-COVID products, contributions from launched and acquired medicines, and continued cost-control efforts. Chief Executive Officer Albert Bourla said the company’s launched and

Global pharmaceutical company Pfizer (NYSE:PFE) reported revenue ahead of Wall Street’s expectations in Q3 2026, but sales were flat year on year at $16.58 b...

Pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) reported Q3 2026 results beating Wall Street’s revenue expectations, with sales up 10% year on ye...

Animal health company Zoetis (NYSE:ZTS) will be reporting earnings this Thursday before market hours. Here’s what to look for. Zoetis missed analysts’ revenu...

Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) will be announcing earnings results this Thursday before the bell. Here’s what investors should...

Pfizer lifts guidance as newer drugs grow, even as COVID sales keep falling.

BioNTech (NASDAQ:BNTX) reported third-quarter 2026 revenue of €1.3 billion, down from €1.5 billion a year earlier, as lower demand for its COVID-19 vaccine weighed on results. The company raised the midpoint of its full-year revenue outlook while highlighting progress across its late-stage oncology

Pfizer's revenue didn't grow, but the mix underneath it changed a lot.

The healthcare stock may finally have the catalyst that it needs to take off before the end of the year.

Global pharmaceutical company Pfizer (NYSE:PFE) reported Q3 2026 results exceeding the market’s revenue expectations, but revenue was flat year on year at $1...

Pfizer stock slipped a fraction early Tuesday, but the company raised its guidance for the year and named a new CFO.

Panama City, Guanacaste in Costa Rica and Lagos, Portugal top one investor's list for rental income and long-term growth, with Portuguese mortgages from 2.6%.

The market for GLP-1 drugs is forecast to explode. It may be understated still.

Personal health and wellness is one of the many secular tailwinds for healthcare companies. Shareholders who bet on the industry have been rewarded lately as...

Global pharmaceutical company Pfizer (NYSE:PFE) will be reporting results this Tuesday before market open. Here’s what to expect. Pfizer beat analysts’ reven...

Pfizer's post-COVID comeback is still only in the early stages.